Pier L. Piovano

Alessandria, Italy

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications

Corrigendum to 'Real-life management of stage III non-small cell lung cancer patients in Italy: the BE-PACIFIC observational study' [Cancer Treat Res Commun. 2026:47:101143].

Corrigendum to 'Real-life management of stage III non-small cell lung cancer patients in Italy: the BE-PACIFIC observational study' [Cancer Treat Res Commun. 2026:47:101143].

Journal: Cancer treatment and research communications
Published: August 25, 2026

Real-life management of stage III non-small cell lung cancer patients in Italy: the BE-PACIFIC observational study.

Real-life management of stage III non-small cell lung cancer patients in Italy: the BE-PACIFIC observational study.

Journal: Cancer treatment and research communications
Published: March 24, 2025

Safety of extended interval dosing immune checkpoint inhibitors: a multicenter cohort study.

Safety of extended interval dosing immune checkpoint inhibitors: a multicenter cohort study.

Journal: Journal of the National Cancer Institute
Published: November 08, 2022

A feasibility exploratory study of a novel modality of using patient-reported outcomes (PROsEXPLOR) in the real world.

A feasibility exploratory study of a novel modality of using patient-reported outcomes (PROsEXPLOR) in the real world.

Journal: Tumori
Published: May 21, 2020

Be-TeaM: An Italian real-world observational study on second-line therapy for EGFR-mutated NSCLC patients.

Be-TeaM: An Italian real-world observational study on second-line therapy for EGFR-mutated NSCLC patients.

Journal: Lung cancer (Amsterdam, Netherlands)
Published: September 16, 2019

Outcomes of First-Generation EGFR-TKIs Against Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Post Hoc Analysis of the BE-POSITIVE Study.

Outcomes of First-Generation EGFR-TKIs Against Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Post Hoc Analysis of the BE-POSITIVE Study.

Journal: Clinical lung cancer
Published: January 24, 2017

BE-POSITIVE: Beyond progression after tyrosine kinase inhibitor in EGFR- positive non small cell lung cancer patients: Results from a multicenter Italian observational study.

BE-POSITIVE: Beyond progression after tyrosine kinase inhibitor in EGFR- positive non small cell lung cancer patients: Results from a multicenter Italian observational study.

Journal: Lung cancer (Amsterdam, Netherlands)
Published: November 25, 2015

Neoadjuvant therapy and mini-invasive total mesorectal excision for rectal cancer: feasibility and outcome analysis from a single institution prospectively collected data base.

Neoadjuvant therapy and mini-invasive total mesorectal excision for rectal cancer: feasibility and outcome analysis from a single institution prospectively collected data base.

Journal: Tumori
Published: February 08, 2013
Showing 1-8 of 8

Last Updated: 09/26/2026